First-in-Class

First-in-Class Biopharma is a clinical-stage biotechnology company based in Beijing, China, focused on developing innovative treatments for metabolic disorders and oncology. The company utilizes a proprietary drug discovery platform to engineer multi-target agonists that address complex disease pathways simultaneously. Its lead program, F-632, is a tri-agonist targeting the GLP-1, GIP, and glucagon receptors, currently being evaluated for indications such as type 2 diabetes and obesity. First-in-Class Biopharma aims to establish a leadership position in the metabolic space by delivering therapies with enhanced efficacy and safety profiles.